Article Text

Download PDFPDF

Clinical Science
Efficacy and tolerability of bimatoprost versus travoprost in patients previously on latanoprost: a 3-month, randomised, masked-evaluator, multicentre study
  1. J A Kammer1,
  2. B Katzman2,
  3. S L Ackerman3,
  4. D A Hollander4
  1. 1
    Vanderbilt Eye Institute, Nashville, Tennessee, USA
  2. 2
    West Coast Eye Care Associates, San Diego, California, USA
  3. 3
    Philadelphia Eye Associates, Philadelphia, Pennsylvania, USA
  4. 4
    Allergan, Irvine, California, USA
  1. Correspondence to Dr J A Kammer, Vanderbilt Eye Institute, 2311 Pierce Ave, Nashville, TN 37232-8808, USA; jeffrey.kammer{at}


Aim: To evaluate the efficacy and safety of replacing latanoprost with another prostaglandin analogue (PGA) in patients with glaucoma or ocular hypertension requiring additional intraocular pressure (IOP) lowering while on latanoprost.

Methods: Prospective, randomised, investigator-masked, multicentre clinical trial. Patients on latanoprost 0.005% monotherapy requiring additional IOP lowering discontinued latanoprost and were randomised to bimatoprost 0.03% (n = 131) or travoprost 0.004% (n = 135). IOP was measured at latanoprost-treated baseline and after 1 month and 3 months of replacement therapy.

Results: Baseline mean diurnal IOP on latanoprost was similar between groups. The mean diurnal IOP was significantly lower with bimatoprost than with travoprost at 1 month (p = 0.009) and 3 months (p = 0.024). Overall, 22.0% of bimatoprost patients versus 12.1% of travoprost patients achieved a ⩾15% reduction in diurnal IOP from latanoprost-treated baseline at both months 1 and 3 (p = 0.033). At month 3, the additional mean diurnal IOP reduction from latanoprost-treated baseline was 2.1 (95% CI 1.7 to 2.5) mm Hg (11.0%) with bimatoprost and 1.4 (95% CI 0.9 to 1.8) mm Hg (7.4%) with travoprost (p = 0.024). At 3 months, 11.5% of bimatoprost and 16.5% of travoprost patients demonstrated a ⩾1-grade increase in physician-graded conjunctival hyperaemia (p = 0.288). Hyperaemia was reported as a treatment-related adverse event in 3.1% of bimatoprost and 1.5% of travoprost patients (p = 0.445).

Conclusion: Patients on latanoprost requiring lower IOP achieved a greater additional short-term diurnal IOP reduction when latanoprost was replaced by bimatoprost compared with travoprost. Low rates of hyperaemia were observed in patients treated with bimatoprost or travoprost after switching from latanoprost.

View Full Text

Statistics from


  • Funding This study was sponsored by Allergan.

  • Competing interests JAK has received lecture honoraria from Allergan and has been reimbursed for attending conferences. BK was involved in this study sponsored by Allergan and declares no other financial interests. SLA attended and was compensated for a 2-day consultants’ meeting sponsored by Alcon Labs in 2008. The practice is also involved in various clinical research projects sponsored by Allergan, Alcon, Pfizer and ISTA. From time to time, it may have a similar involvement with other pharmaceutical and device companies. DAH in an employee of Allergan.

  • Ethics approval Ethics approval was provided by the Institutional Review Board at each of the 17 participating sites.

  • Patient consent Obtained.

  • Provenance and Peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.